Table 4.
Bleeding rates among those who received tPA or thrombectomy and those who didn't subcategorized by antiplatelet therapy groups.
| Received tPA or Thrombectomy | Yes ( n = 171) | No ( n = 206) | ||||
|---|---|---|---|---|---|---|
| Not DAPT (n = 132) | DAPT (n = 39) | P-value | Not DAPT (n = 104) | DAPT (n = 102) | P-value | |
| Major bleeding | 10.6% | 2.6% | 0.20 | 3.9% | 2% | 0.68 |
| Asymptomatic ICH | 15.2% | 2.6% | 0.05 | 5.8% | 1.0% | 0.12 |
| Symptomatic ICH (NIHSS any change) | 9.1% | 2.6% | 0.30 | 2.9% | 0% | 0.25 |
| Symptomatic ICH (NIHSS change >/=4) | 2.3% | 2.6% | 1.00 | 0% | 0% | 1.00 |
| ICH classification | ||||||
| HI1 | 3.8% | 2.6% | 1.00 | 6.7% | 0% | 0.01 |
| HI2 | 5.3% | 0% | 0.35 | 1.0% | 0% | 1.00 |
| PH1 | 3.8% | 0% | 0.59 | 0% | 0% | 1.00 |
| PH2 | 6.8% | 2.6% | 0.46 | 1.0% | 0% | 1.00 |
| Other (Any SAH, IVH or SDH) | 13.6% | 2.6% | 0.08 | 2.9% | 1.0% | 0.62 |
tPA, tissue plasminogen activator; DAPT, dual antiplatelet therapy; ICH, intracranial hemorrhage; NIHSS, National Institute of Health stroke scale; HI1, hemorrhagic transformation type 1 (defined as small petechiae without mass effect); HI2, hemorrhagic transformation type 2 (defined as more confluent petechiae without mass effect); PH1, parenchymal hematoma type 1 (defined as hematoma <30% of infarct bed with some mild mass effect); PH2, parenchymal hematoma type 2 (defined as hematoma >30% of infarct bed with significant mass effect); SAH, subarachnoid hemorrhage; IVH, intraventricular hemorrhage; SDH, subdural hemorrhage.